Evidence map›Paper›PMID 38245698›Full record

ArticleSubstance abuse treatment, prevention, and policy2024

Brain-derived neurotrophic factor serum levels as a candidate biomarker for withdrawal in crack heroin dependence.

Enam Alhagh Charkhat Gorgich, Mohammad Gol Rigi, Hamed Fanaei, Houman Parsaei, Abdolhakim Ghanbarzehi

Open access · goldAbstract read
In one paragraph

Article in Substance abuse treatment, prevention, and policy, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 4 institutions in 1 country.

Enam Alhagh Charkhat GorgichDepartment of Anatomy, School of Medicine, Iranshahr University of Medical Sciences, Iranshahr, Iran.ORCID 0000-0001-6817-8532
Mohammad Gol RigiDepartment of Law, Hatef Higher Education Institute, Zahedan, Iran.
Hamed FanaeiPregnancy Health Research Center, Zahedan University of Medical Sciences, Zahedan, Iran.ORCID 0000-0002-5420-5269
Houman ParsaeiNervous System Stem Cells Research Center, Semnan University of Medical Sciences, Semnan, Iran.ORCID 0000-0002-1820-8913
Abdolhakim GhanbarzehiStudent Research Committee, Iran University of Medical Sciences, Tehran, Iran. Abdolhakimghanbarzehi@yahoo.com.ORCID 0000-0002-1708-8745
Iranshahr University · IRIran University of Medical Sciences · IRSemnan University of Medical Sciences · IRZahedan University of Medical Sciences · IR

Funding

Iranshahr University of Medical Sciences, Iranshahr, Iran 9413-16
6 · The paper itself

Abstract

backgroundCrack heroin is a novel opiate derivative with highly addictive properties and unfamiliar health consequences. It causes a variety of brain dysfunctions that are mediated by neurochemical alterations and abnormal neuroplasticity. Brain-derived neurotrophic factor (BDNF) is a widely recognized biological marker implicated in the neuropathology of substance use during substance use disorder and withdrawal. Its involvement can significantly contribute to the severity of withdrawal symptoms. Hence, this study aimed to evaluate BDNF levels in crack heroin users before and after withdrawal.

methodsIn this cross-sectional study, 148 male participants were recruited and divided into two groups: persons with crack heroin use disorder (n = 74) and the controls (n = 74). The BDNF serum levels were measured in both crack heroin users and control groups upon hospitalization and again after twenty-one days of withdrawal using the enzyme-linked immunosorbent assay.

resultsThe results demonstrated that BDNF levels in persons with crack heroin use disorder upon admission were significantly lower than the levels observed upon discharge and in the control group (p < 0.05). Additionally, a significant difference in BDNF levels was found between persons with crack heroin use disorder at admission and discharge (p = 0.038). Furthermore, BDNF levels showed an inverse correlation with the daily dose of substance use (r= -0.420, p = 0.03) and the duration of crack heroin use (r= -0.235, p = 0.001).

conclusionsA progressive increment in BDNF levels during early detoxification is associated with the daily amount of substance use and the duration of substance use. Our findings suggest that changes in BDNF serum levels during crack heroin use disorder and withdrawal could serve as potential biomarkers for assessing the intensity of withdrawal symptoms and substance use-related behaviors.

Indexed as

Heroin DependenceSubstance Withdrawal SyndromeBiomarkersBrain-Derived Neurotrophic FactorCross-Sectional StudiesHeroinHumansMaleBDNF protein, humanBiomarkersBrain-Derived Neurotrophic FactorHeroinBiomarkersBrain-derived neurotrophic factorCrack heroinNeuroplasticityOpiate dependenceWithdrawal

Identifiers

PMID38245698
PMCPMC10800061
OpenAlexW4391057522

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.